BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29621097)

  • 81. Molecular characteristics of meningiomas.
    Lee YS; Lee YS
    J Pathol Transl Med; 2020 Jan; 54(1):45-63. PubMed ID: 31964111
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Investigation of the status of immune checkpoint molecules in meningiomas by immunohistochemistry.
    Saygin I; Cakir E; Kazaz SN; Guvercin AR; Eyuboglu I; Ustaoglu MM
    Turk Neurosurg; 2023 Aug; ():. PubMed ID: 38874241
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Further delineation of DDX3X syndrome.
    Chanes NM; Wong J; Lacassie Y
    Clin Dysmorphol; 2019 Jul; 28(3):151-153. PubMed ID: 30817323
    [No Abstract]   [Full Text] [Related]  

  • 84. Magnetic resonance imaging of meningiomas: a pictorial review.
    Watts J; Box G; Galvin A; Brotchie P; Trost N; Sutherland T
    Insights Imaging; 2014 Feb; 5(1):113-22. PubMed ID: 24399610
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Small Cell Lung Carcinoma Metastasis to Atypical Meningioma: Importance of Perfusion Magnetic Resonance Imaging Graphics in Differential Diagnosis.
    Danisman MÇ; Koplay M; Paksoy Y; Keleşoğlu KS; Karabağlı P; Köktekir E
    World Neurosurg; 2019 Apr; 124():410-413. PubMed ID: 30703595
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [On an atypical case of neoplastic occlusion].
    DUFOUR ; DUBOURG E
    J Med Bord; 1949 Sep; 126(9):451. PubMed ID: 18141855
    [No Abstract]   [Full Text] [Related]  

  • 87. Meningiomas: Are they curable?
    Goel A; Kothari M
    J Craniovertebr Junction Spine; 2016; 7(3):133-4. PubMed ID: 27630473
    [No Abstract]   [Full Text] [Related]  

  • 88. Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.
    Aung TM; Ngamjarus C; Proungvitaya T; Saengboonmee C; Proungvitaya S
    PLoS One; 2024; 19(5):e0303337. PubMed ID: 38758750
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy.
    Arna AB; Patel H; Singh RS; Vizeacoumar FS; Kusalik A; Freywald A; Vizeacoumar FJ; Wu Y
    Front Oncol; 2022; 12():1087989. PubMed ID: 36761420
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Molecular docking, synthesis, and biological evaluation of 7-azaindole-derivative (7AID) as novel anti-cancer agent and potent DDX3 inhibitor:-an in silico and in vitro approach.
    Doneti R; Pasha A; Botlagunta M; Heena SK; Mutyala VVVP; Pawar SC
    Med Oncol; 2022 Sep; 39(11):179. PubMed ID: 36048256
    [TBL] [Abstract][Full Text] [Related]  

  • 91. DDX3X: structure, physiologic functions and cancer.
    Mo J; Liang H; Su C; Li P; Chen J; Zhang B
    Mol Cancer; 2021 Feb; 20(1):38. PubMed ID: 33627125
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Nrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas.
    Tsai WC; Hueng DY; Lin CR; Yang TC; Gao HW
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187376
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
    Modha A; Gutin PH
    Neurosurgery; 2005 Sep; 57(3):538-50; discussion 538-50. PubMed ID: 16145534
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Atypical and malignant meningiomas: a clinicopathological review.
    Mahmood A; Caccamo DV; Tomecek FJ; Malik GM
    Neurosurgery; 1993 Dec; 33(6):955-63. PubMed ID: 8134008
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Applying DDX3X Biomarker to Discriminate Atypical from Benign Meningiomas in Tissue Microarray.
    Tsai WC; Hueng DY; Lin CR; Yang TCK; Nieh S; Gao HW
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):263-267. PubMed ID: 29621097
    [TBL] [Abstract][Full Text] [Related]  

  • 96. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
    Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
    Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
    [TBL] [Abstract][Full Text] [Related]  

  • 97. ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas.
    Tsai WC; Hueng DY; Nieh S; Gao HW
    J Clin Pathol; 2017 Feb; 70(2):162-167. PubMed ID: 27451434
    [TBL] [Abstract][Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.